Physciosporin suppresses the proliferation, motility and tumourigenesis of colorectal cancer cells

Taf,, İ,sa,Han, Jin,Park, So-Yeon,Yang, Yi,Zhou, Rui,Gamage, Chathurika D.B.,Van Nguyen, Tru,Lee, Ji-Yoon,Choi, Yong Jae,Yu, Young Hyun,Moon, Kyung-Sub,Kim, Kyung Keun,Ha, Hyung-Ho,Kim, Sang Elsevier 2019 Phytomedicine Vol.56 No.-

<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Lichens, which represent symbiotic associations of fungi and algae, are potential sources of numerous natural products. Physciosporin (PHY) is a potent secondary metabolite found in lichens and was recently reported to inhibit the motility of lung cancer cells via novel mechanisms.</P> <P><B>Purpose</B></P> <P>The present study investigated the anticancer potential of PHY on colorectal cancer (CRC) cells.</P> <P><B>Methods</B></P> <P>PHY was isolated from lichen extract by preparative TLC. The effect of PHY on cell viability, motility and tumourigenicity was elucidated by MTT assay, hoechst staining, flow cytometric analysis, transwell invasion and migration assay, soft agar colony formation assay, Western blotting, qRT-PCR and PCR array <I>in vitro</I> as well as tumorigenicity study <I>in vivo</I>.</P> <P><B>Results</B></P> <P>PHY decreased the viability of various CRC cell lines (Caco2, CT26, DLD1, HCT116 and SW620). Moreover, PHY elicited cytotoxic effects by inducing apoptosis at toxic concentrations. At non-toxic concentrations, PHY dose-dependently suppressed the invasion, migration and colony formation of CRC cells. PHY inhibited the motility of CRC cells by suppressing epithelial-mesenchymal transition and downregulating actin-based motility markers. In addition, PHY downregulated β-catenin and its downstream target genes cyclin-D1 and c-Myc. Moreover, PHY modulated KAI1 C-terminal-interacting tetraspanin and KAI1 expression, and downregulated the downstream transcription factors c-jun and c-fos. Finally, PHY administration showed considerable bioavailability and effectively decreased the growth of CRC xenografts in mice without causing toxicity.</P> <P><B>Conclusion</B></P> <P>PHY suppresses the growth and motility of CRC cells via novel mechanisms.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>

Effect of Bacillus subtilis Natto on Meat Quality and Skatole Content in TOPIGS Pigs

Sheng, Q.K.,Zhou, K.F.,Hu, H.M.,Zhao, H.B.,Zhang, Y.,Ying, W. Asian Australasian Association of Animal Productio 2016 Animal Bioscience Vol.29 No.5

This study investigated the effect of Bacillus subtilis (B. subtilis) natto on meat quality and skatole in TOPIGS pigs. Sixty TOPIGS pigs were randomly assigned to 3 groups (including 5 pens per group, with 4 pigs in each pen) and fed with basic diet (control group), basic diet plus 0.1% B. subtilis natto (B group), and basic diet plus 0.1% B. subtilis natto plus 0.1% B. coagulans (BB group), respectively. All pigs were sacrificed at 100 kg. Growth performance, meat quality, serum parameters and oxidation status in the three groups were assessed and compared. Most parameters regarding growth performance and meat quality were not significantly different among the three groups. However, compared with the control group, meat $pH_{24}$, fat and feces skatole and the content of Escherichia coli (E. Coli), Clostridium, $NH_3$-N were significantly reduced in the B and BB groups, while serum total cholesterol, high density lipoprotein, the levels of liver P450, CYP2A6, and CYP2E1, total antioxidant capability (T-AOC) and glutathione peroxidase and Lactobacilli in feces were significantly increased in the B and BB groups. Further, the combined supplementation of B. subtilis natto and B. coagulans showed more significant effects on the parameters above compared with B. subtilis, and Clostridium, and $NH_3$-N. Our results indicate that the supplementation of pig feed with B. subtilis natto significantly improves meat quality and flavor, while its combination with B. coagulans enhanced these effects.

Effects of Combining Feed Grade Urea and a Slow-release Urea Product on Performance, Dietary Energetics and Carcass Characteristics of Feedlot Lambs Fed Finishing Diets with Different Starch to Acid Detergent Fiber Ratios

Estrada-Angulo, A.,Lopez-Soto, M.A.,Rivera-Mendez, C.R.,Castro, B.I.,Rios, F.G.,Davila-Ramos, H.,Barreras, A.,Urias-Estrada, J.D.,Zinn, R.A.,Plascencia, A. Asian Australasian Association of Animal Productio 2016 Animal Bioscience Vol.29 No.12

Recent findings have shown that microbial nitrogen flow and digestible energy of diets are increased when urea is combined with a slow-release urea (SRU) in diets with a starch to acid detergent fibre ratio (S:F) 4:1. This affect is attributable to enhanced synchrony between ruminal N availability for microbial growth and carbohydrate degradation. To verify the magnitude of this effects on lamb performance, an experiment was conducted to evaluate the effects of combining urea and a SRU in diets containing S:F ratios of 3:1, 4:1, or 5:1 on performance, dietary energetics and carcass characteristics of finishing lambs. For that, 40 Pelibuey${\times}$Katahdin lambs ($36.65{\pm}3kg$) were assigned to one of five weight groupings in 20 pens (5 repetition/treatments). The S:F ratio in the diet was manipulated by partially replacing the corn grain and dried distiller's grain with solubles by forage (wheat straw) and soybean meal to reach S:F ratios of 3:1, 4:1 or 5:1. An additional treatment of 4:1 S:F ratio with 0.8% urea as the sole source of non-protein nitrogen was used as a reference for comparing the effect of urea combination vs. conventional urea at the same S:F ratio. There were no treatment effects on dry matter intake (DMI). Compared the urea combination vs urea at the same S:F ratio, urea combination increased (p<0.01) average daily gain (ADG, 18.3%), gain for feed (G:F, 9.5%), and apparent energy retention per unit DMI (8.2%). Irrespective of the S:F ratio, the urea combination improved the observed-to-expected dietary ratio and apparent retention per unit DMI was maximal (quadratic effect, $p{\leq}0.03$) at an S:F ratio of 4:1, while the conventional urea treatment did not modify the observed-to-expected net energy ratio nor the apparent retention per unit DMI at 4:1 S:F ratio. Urea combination group tended (3.8%, p = 0.08) to have heavier carcasses with no effects on the rest of carcass characteristics. As S:F ratio increased, ADG, G:F, dietary net energy, carcass weight, dressing percentage and longissimus thoracis (LM) area increased linearly ($p{\leq}0.02$). Combining urea and a slow-release urea product results in positive effects on growth performance and dietary energetics, but the best responses are apparently observed when there is a certain proportion (S:F ratio = 4:1) of starch to acid detergent fibre in the diet.

Thermotropic Phase Transition of Benzodithiophene Copolymer Thin Films and Its Impact on Electrical and Photovoltaic Characteristics

Ko, Sangwon,Kim, Do Hwan,Ayzner, Alexander L.,Mannsfeld, Stefan C. B.,Verploegen, Eric,Nardes, Alexander M.,Kopidakis, Nikos,Toney, Michael F.,Bao, Zhenan American Chemical Society 2015 Chemistry of materials Vol.27 No.4

<P>We observed a thermotropic phase transition in poly[3,4-dihexyl thiophene-2,2′:5,6′-benzo[1,2-b:4,5-b′]dithiophene] (<B>PDHBDT</B>) thin films accompanied by a transition from a random orientation to an ordered lamellar phase via a nearly hexagonal lattice upon annealing. We demonstrate the effect of temperature-dependent molecular packing on charge carrier mobility (μ) in organic field-effect transistors (OFETs) and photovoltaic characteristics, such as exciton diffusion length (<I>L</I><SUB>D</SUB>) and power conversion efficiency (PCE), in organic solar cells (OSCs) using <B>PDHBDT</B>. The μ was continuously improved with increasing annealing temperature and <B>PDHBDT</B> films annealed at 270 °C resulted in a maximum μ up to 0.46 cm<SUP>2</SUP>/(V s) (μ<SUB>avg</SUB> = 0.22 cm<SUP>2</SUP>/(V s)), which is attributed to the well-ordered lamellar structure with a closer π–π stacking distance of 3.5 Å as shown by grazing incidence-angle X-ray diffraction (GIXD). On the other hand, <B>PDHBDT</B> films with a random molecular orientation are more effective in photovoltaic devices than films with an ordered hexagonal or lamellar phase based on current–voltage characteristics of <B>PDHBDT</B>/C60 bilayer solar cells. This observation corresponds to an enhanced dark current density (<I>J</I><SUB>D</SUB>) and a decreased <I>L</I><SUB>D</SUB> upon annealing. This study provides insight into the dependence of charge transport and photovoltaic characteristics on molecular packing in polymer semiconductors, which is crucial for the management of charge and energy transport in a range of organic optoelectronic devices.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/cmatex/2015/cmatex.2015.27.issue-4/cm503773j/production/images/medium/cm-2014-03773j_0006.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/cm503773j'>ACS Electronic Supporting Info</A></P>

First observation of the decay B@?_s⁰→D⁰K^@?0 and a measurement of the ratio of branching fractions B(B@?_s⁰→D⁰K^@?0)B(B@?⁰→D⁰ρ⁰)

LHCb Collaboration,Aaij, R.,Abellan Beteta, C.,Adeva, B.,Adinolfi, M.,Adrover, C.,Affolder, A.,Ajaltouni, Z.,Albrecht, J.,Alessio, F.,Alexander, M.,Alkhazov, G.,Alvarez Cartelle, P.,Alves, A.A.,Amato, North-Holland Pub. Co 2011 Physics letters: B Vol.706 No.1

The first observation of the decay B@?<SUB>s</SUB><SUP>0</SUP>→D<SUP>0</SUP>K<SUP>@?0</SUP> using pp data collected by the LHCb detector at a centre-of-mass energy of 7 TeV, corresponding to an integrated luminosity of 36 pb<SUP>-1</SUP>, is reported. A signal of 34.4+/-6.8 events is obtained and the absence of signal is rejected with a statistical significance of more than nine standard deviations. The B@?<SUB>s</SUB><SUP>0</SUP>→D<SUP>0</SUP>K<SUP>@?0</SUP> branching fraction is measured relative to that of B@?<SUP>0</SUP>→D<SUP>0</SUP>ρ<SUP>0</SUP>: B(B@?<SUB>s</SUB><SUP>0</SUP>→D<SUP>0</SUP>K<SUP>@?0</SUP>)B(B@?<SUP>0</SUP>→D<SUP>0</SUP>ρ<SUP>0</SUP>)=1.48+/-0.34+/-0.15+/-0.12, where the first uncertainty is statistical, the second systematic and the third is due to the uncertainty on the ratio of the B<SUP>0</SUP> and B<SUB>s</SUB><SUP>0</SUP> hadronisation fractions.

Bs0lifetime measurement in theCP-odd decay channelBs0→J/ψ f0(980)

Abazov, V. M.,Abbott, B.,Acharya, B. S.,Adams, M.,Adams, T.,Agnew, J. P.,Alexeev, G. D.,Alkhazov, G.,Alton, A.,Askew, A.,Atkins, S.,Augsten, K.,Aushev, V.,Aushev, Y.,Avila, C.,Badaud, F.,Bagby, L.,Bal American Physical Society 2016 Physical Review D Vol.94 No.1

<P>The lifetime of the B-s(0) meson is measured in the decay channel B-s(0) -> J/Psi pi(+)pi(-) with 880 <= M pi+pi- <= 1080 MeV/c(2), which is mainly a CP-odd state and dominated by the f(0)(980) resonance. In 10.4 fb(-1) of data collected with the D0 detector in Run II of the Tevatron, the lifetime of the B-s(0) meson is measured to be tau(B-s(0)) = 1.70 +/- 0.14(stat) +/- 0.05(syst) ps. Neglecting CP violation in B-s(0)/(B) over bar (0)(s) mixing, the measurement can be translated into the width of the heavy mass eigenstate of the B-s(0), Gamma(H) = 0.59 +/- 0.05(stat) +/- 0.02(syst) ps(-1).</P>

Association of genetic variation in <i>FTO</i> with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians

Li, H.,Kilpelä,inen, T. O.,Liu, C.,Zhu, J.,Liu, Y.,Hu, C.,Yang, Z.,Zhang, W.,Bao, W.,Cha, S.,Wu, Y.,Yang, T.,Sekine, A.,Choi, B. Y.,Yajnik, C. S.,Zhou, D.,Takeuchi, F.,Yamamoto, K.,Chan, J. C.,Man Springer-Verlag 2012 Diabetologia Vol.55 No.4

<P><B>Aims/hypothesis</B></P><P><I>FTO</I> harbours the strongest known obesity-susceptibility locus in Europeans. While there is growing evidence for a role for <I>FTO</I> in obesity risk in Asians, its association with type 2 diabetes, independently of BMI, remains inconsistent. To test whether there is an association of the <I>FTO</I> locus with obesity and type 2 diabetes, we conducted a meta-analysis of 32 populations including 96,551 East and South Asians.</P><P><B>Methods</B></P><P>All studies published on the association between <I>FTO</I>-rs9939609 (or proxy [<I>r</I><SUP>2</SUP> > 0.98]) and BMI, obesity or type 2 diabetes in East or South Asians were invited. Each study group analysed their data according to a standardised analysis plan. Association with type 2 diabetes was also adjusted for BMI. Random-effects meta-analyses were performed to pool all effect sizes.</P><P><B>Results</B></P><P>The <I>FTO</I>-rs9939609 minor allele increased risk of obesity by 1.25-fold/allele (<I>p</I> = 9.0 × 10<SUP>−19</SUP>), overweight by 1.13-fold/allele (<I>p</I> = 1.0 × 10<SUP>−11</SUP>) and type 2 diabetes by 1.15-fold/allele (<I>p</I> = 5.5 × 10<SUP>−8</SUP>). The association with type 2 diabetes was attenuated after adjustment for BMI (OR 1.10-fold/allele, <I>p</I> = 6.6 × 10<SUP>−5</SUP>). The <I>FTO</I>-rs9939609 minor allele increased BMI by 0.26 kg/m<SUP>2</SUP> per allele (<I>p</I> = 2.8 × 10<SUP>−17</SUP>), WHR by 0.003/allele (<I>p</I> = 1.2 × 10<SUP>−6</SUP>), and body fat percentage by 0.31%/allele (<I>p</I> = 0.0005). Associations were similar using dominant models. While the minor allele is less common in East Asians (12–20%) than South Asians (30–33%), the effect of <I>FTO</I> variation on obesity-related traits and type 2 diabetes was similar in the two populations.</P><P><B>Conclusions/interpretation</B></P><P><I>FTO</I> is associated with increased risk of obesity and type 2 diabetes, with effect sizes similar in East and South Asians and similar to those observed in Europeans. Furthermore, <I>FTO</I> is also associated with type 2 diabetes independently of BMI.</P><P><B>Electronic supplementary material</B></P><P>The online version of this article (doi:10.1007/s00125-011-2370-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.</P>

Hyaluronidase-inhibitory activities of glycosaminoglycans from Liparis tessellatus eggs

Ticar, B.F.,Rohmah, Z.,Mussatto, S.I.,Lim, J.M.,Park, S.,Choi, B.D. Applied Science Publishers 2017 Carbohydrate polymers Vol.161 No.-

Polysaccharide fractions isolated from L. tessellatus eggs were purified and eluted using the DEAE-sepharose fast flow column. These were collected, tested and pooled based on their sugars content: F1, F2, and F3 which contain 26.8, 23.3, and 20.2% sulfated glycans; 34.5, 38.2, and 45.0% uronic acids; and 23.5, 19.0, and 7.5% acetylhexosamines and hexosamines, respectively. Hyaluronidase inhibitory effects of the fractions are in the order F3>F2>F1>Ascorbic acid, with F3 having the highest inhibition among the fractions and that of the standard, ascorbic acid. The electrospray ionization tandem mass spectrometry (ESI-MS/MS) confirmed the presence of uronic acids on F3, which could be a <SUP>0,2</SUP>A<SUB>2</SUB> fragment plus loss of methyl group which is very common among non-methylated, sulfated disaccharides.

Measurement of theBc±production cross section inpp¯collisions ats=1.96 TeV

Aaltonen, T.,Amerio, S.,Amidei, D.,Anastassov, A.,Annovi, A.,Antos, J.,Apollinari, G.,Appel, J. A.,Arisawa, T.,Artikov, A.,Asaadi, J.,Ashmanskas, W.,Auerbach, B.,Aurisano, A.,Azfar, F.,Badgett, W.,Bae American Physical Society 2016 Physical Review D Vol.93 No.5

<P>We describe a measurement of the ratio of the cross sections times branching fractions of the B-c(+) meson in the decay mode B-c(+) -> J/psi mu(+)nu to the B+ meson in the decay mode B+ -> J/psi K+ in proton-antiproton collisions at center-of-mass energy root s = 1.96 TeV. The measurement is based on the complete CDF Run II data set, which comes from an integrated luminosity of 8.7 fb(-1). The ratio of the production cross sections times branching fractions for B-c(+) and B+ mesons with momentum transverse to the beam greater than 6 GeV/c and rapidity magnitude smaller than 0.6 is 0.211 +/- 0.012(stat)(-0.020)(+0.021)(syst). Using the known B+ -> J/psi K+ branching fraction, the known B+ production cross section, and a selection of the predicted B-c(+) -> J/psi mu(+nu) branching fractions, the range for the total B-c(+) production cross section is estimated.</P>

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Knox, J. J.,Barrios, C. H.,Kim, T. M.,Cosgriff, T.,Srimuninnimit, V.,Pittman, K.,Sabbatini, R.,Rha, S. Y.,Flaig, T. W.,Page, R. D.,Beck, J. T.,Cheung, F.,Yadav, S.,Patel, P.,Geoffrois, L.,Niolat, J.,B Oxford University Press 2017 ANNALS OF ONCOLOGY Vol.28 No.6

<P><B>Background</B></P><P>RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.</P><P><B>Patients and methods</B></P><P>Patients received either first-line everolimus followed by second-line sunitinib at progression (<I>n = </I>238) or first-line sunitinib followed by second-line everolimus (<I>n = </I>233). Secondary end points were combined first- and second-line progression-free survival (PFS), OS, and safety. The impacts of neutrophil lymphocyte ratio (NLR) and baseline levels of soluble biomarkers on OS were explored.</P><P><B>Results</B></P><P>At final analysis, median duration of exposure was 5.6 months for everolimus and 8.3 months for sunitinib. Median combined PFS was 21.7 months [95% confidence interval (CI) 15.1–26.7] with everolimus-sunitinib and 22.2 months (95% CI 16.0–29.8) with sunitinib-everolimus [hazard ratio (HR)<SUB>EVE-SUN/SUN-EVE</SUB>, 1.2; 95% CI 0.9–1.6]. Median OS was 22.4 months (95% CI 18.6–33.3) for everolimus-sunitinib and 29.5 months (95% CI 22.8–33.1) for sunitinib-everolimus (HR<SUB>EVE-SUN/SUN-EVE</SUB>, 1.1; 95% CI 0.9–1.4). The rates of grade 3 and 4 adverse events suspected to be related to second-line therapy were 47% with everolimus and 57% with sunitinib. Higher NLR and 12 soluble biomarker levels were identified as prognostic markers for poor OS with the association being largely independent of treatment sequences.</P><P><B>Conclusions</B></P><P>Results of this final OS analysis support the sequence of sunitinib followed by everolimus at progression in patients with mRCC. The safety profiles of everolimus and sunitinib were consistent with those previously reported, and there were no unexpected safety signals.</P><P><B>Clinical Trials number</B></P><P>ClinicalTrials.gov identifier, NCT00903175</P>